Trial Profile
Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Apr 2023
Price :
$35
*
At a glance
- Drugs Sildenafil (Primary) ; Sorafenib (Primary) ; Valproic acid (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 27 Oct 2021 Planned End Date changed from 30 Jun 2022 to 30 Oct 2027.
- 14 Jul 2020 Planned End Date changed from 30 Jun 2021 to 30 Jun 2022.
- 14 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 30 Jun 2021.